Merck & Co. Gets FDA Nod to Manufacture Bulk Vaccine at North Carolina Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck & Co. Gets FDA Nod to Manufacture Bulk Vaccine at North Carolina Facility


Merck & Co. has received FDA approval to manufacture bulk varicella, used in in Merck’s vaccines to protect against chickenpox and shingles, at the company’s site in Durham, North Carolina. The approval will enable the site to produce bulk varicella supply for the United States  and help boost Merck’s overall global supply capabilities.

In 2010, the site was approved to produce finished chickenpox vaccines. In the longer term, Merck plans for the site to produce bulk and finished product for other Merck childhood vaccines and for its shingles vaccines, according to a Sept. 4, 2013 Merck press release.

Prior to this licensure, all global bulk supplies for Merck’s varicella-containing vaccines were produced at the company’s facility in West Point, Pennsylvania. The Durham facility is part of Merck’s more than $1-billion investment in its vaccine-manufacturing capabilities during the past nine years. The company also modernized and expanded vaccine operations at its facilities in West Point, Pennsylvania and Elkton, Virginia and built a new facility in Carlow, Ireland, which is scheduled to be licensed in 2014. Merck broke ground for the Durham site in 2004.

Source: Merck & Co.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here